BioSpace News Archive

Tharimmune, Inc. announced today that it will effect a 1-for-25 reverse stock split of its issued and outstanding shares of common stock.

Exact Sciences Corp. today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware.

Adlai Nortye Ltd. today announced the Completion of Patient Enrollment in Global Phase III Clinical Trial (BURAN) of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC.

GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced an increase of clinical cases in the United States using its GammaTile® Therapy in patients diagnosed with several brain tumor types.

Serina Therapeutics, Inc. today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.

The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly diagnosed glioblastoma with unmethylated MGMT.

Schrödinger, Inc. today reported that on November 13, 2023, the company granted (i) non-statutory stock options to purchase 14,400 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 10,050 shares of the company’s common stock to 13 newly hired employees.

CytoMed Therapeutics Limited today announced its first half of 2023 financial results and provided clinical and corporate updates.

The National Eczema Association (NEA) announces the publication of new research on the burden of prescription treatments for comorbid conditions for patients with atopic dermatitis (AD).

Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, enabling physicians to use the test to help guide treatment decisions for patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC).